3-(2-(4-methoxyphenyl)-2-oxoethyl)-5,5-diphenylimidazolidine-2,4-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-(2-(4-methoxyphenyl)-2-oxoethyl)-5,5-diphenylimidazolidine-2,4-dione
• 英文别名: 3-[2-(4-Methoxyphenyl)-2-oxoethyl]-5,5-diphenylimidazolidine-2,4-dione
• 化学式: C₂₄H₂₀N₂O₄
• 分子量: 400.434
• InChiKey: BZIXIEVSXWQXTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.37
• 重原子数：
  30.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  75.71
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  苯妥英 、 2-氯-4-甲氧基苯乙酮 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 24.0h， 生成 3-(2-(4-methoxyphenyl)-2-oxoethyl)-5,5-diphenylimidazolidine-2,4-dione
  参考文献：
  名称：

  基于5,5-二苯基咪唑烷-2,4-二酮骨架的苯甲酸酯的合成，抗炎，镇痛和COX-1 / 2抑制活性：分子对接研究。

  摘要：

  报道了一组5,5-二苯基咪唑烷-2,4-二酮带有苯胺，苯甲酰基和亚苄基片段2-27的设计，合成和药理活性。体内评估了制备的5,5-二苯基咪唑烷-2,4-二酮衍生物的抗炎，镇痛活性，体外评估了COX-1 / 2抑制作用。在所测试的化合物中，衍生物5、9、10、13和14表现出显着和有效的抗炎和镇痛活性，几乎等同于参考药物塞来昔布。在COX-1 / 2抑制试验中，化合物5、9、10和14表现出较高的COX-2抑制活性（IC50分别为0.70μM，0.44μM，0.61μM和0.41μM），选择性指数（SI）范围为142 -243可比塞来昔布[COX-2（SI）> 333]。这些有效的COX-2抑制剂9、10、13

  DOI：

  10.1016/j.ejmech.2016.03.011

文献信息

• Synthesis, single-crystal, in vitro antitumor evaluation and molecular docking of 3-substitued 5,5-diphenylimidazolidine-2,4-dione derivatives
  作者：Amer M. Alanazi、Adel S. El-Azab、Ibrahim A. Al-Swaidan、Azza R. Maarouf、Eman R. El-Bendary、Mohamed A. Abu El-Enin、Alaa A.-M. Abdel-Aziz

  DOI：10.1007/s00044-013-0597-1

  日期：2013.12

  Series of 3-alkyl, 3-aryl-5,5-diphenylimidazolidine-2,4-diones (2-8) and 3-phenacyl-5,5-diphenylimidazolidine-2,4-diones (9-20) were designed, synthesized, and tested for their antitumor activity. The 13 compounds (3-8, 10-15 and 20) were selected by National Cancer Institute (USA) on the basis of degree of the structure variation and computer modeling techniques for evaluation of their antineoplastic activity. A single dose (10 mu M) of the tested compounds was used in the National Cancer Institute (NCI) 60 cell lines panel assay selected from different nine organs. The tested compounds possessed selective activity against the renal cancer (A498 and UO-31) cell lines. Interestingly, compound 13 showed moderate selective activities towards A498 and UO-31 cell lines, in addition to strong activity against melanoma (MDA-MB-435) cell line and breast cancer cell lines (MCF7) in 114 and 70 %, respectively. Molecular docking study was performed for the most active compound 13 to identify the structural features required for the antitumor activity. The results achieved can be used as a useful template for future development and further derivatization or modification to obtain more potent and selective antitumor agents.The development of novel molecules containing imidazolidine-2,4-dione pharmacophore have shown promising antitumor activities. Compound 13 exploited broad spectrum and potent antitumor activity with the percentages of inhibition range of 28-114 %.
• Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5,5-diphenylimidazolidine-2,4-dione scaffold: Molecular docking studies
  作者：Alaa A.-M. Abdel-Aziz、Adel S. El-Azab、Laila A. Abou-Zeid、Kamal Eldin H. ElTahir、Naglaa I. Abdel-Aziz、Rezk R. Ayyad、Abdulrahman M. Al-Obaid

  DOI：10.1016/j.ejmech.2016.03.011

  日期：2016.6

  The design, synthesis and pharmacological activities of a group of 5,5-diphenylimidazolidine-2,4-dione bearing anilide, phenacyl and benzylidene fragments 2-27 were reported. The prepared 5,5-diphenylimidazolidine-2,4-dione derivatives were evaluated in vivo for anti-inflammatory, analgesic activities and in vitro for COX-1/2 inhibition assay. Among the tested compounds, derivatives 5, 9, 10, 13, and

  报道了一组5,5-二苯基咪唑烷-2,4-二酮带有苯胺，苯甲酰基和亚苄基片段2-27的设计，合成和药理活性。体内评估了制备的5,5-二苯基咪唑烷-2,4-二酮衍生物的抗炎，镇痛活性，体外评估了COX-1 / 2抑制作用。在所测试的化合物中，衍生物5、9、10、13和14表现出显着和有效的抗炎和镇痛活性，几乎等同于参考药物塞来昔布。在COX-1 / 2抑制试验中，化合物5、9、10和14表现出较高的COX-2抑制活性（IC50分别为0.70μM，0.44μM，0.61μM和0.41μM），选择性指数（SI）范围为142 -243可比塞来昔布[COX-2（SI）> 333]。这些有效的COX-2抑制剂9、10、13